DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo


company name or ticker

Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog

Is It Time to Buy This Growth Stock?

Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?

Deals, Deals, Deals: What Made 2014 Such a Big Year for Mergers

The 3 Most Memorable Moments in Healthcare This Year

Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.

The Real Banking Rally; Checking Under the Hood: Jim Cramer's Best Blogs

Activist Investors Torn on Private Equity Partnerships

Goldman's Parker Calls Allergan Pursuit a 'One-time Opportunity'

Dodge & Cox's Top New Buys of Q3

Consumer Health Spending a Welcome Wrinkle for Allergan-Actavis Deal

With consumer spending on "descrtionary items" like elective healthcare procedures, treatments and products on the rise, the combined Actavis and Allergan with its portfolio of cosmetic drugs like Botox will benefit.

Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog

See More Articles...